



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

JUL 22 1992

MEMORANDUM

OFFICE OF  
PESTICIDES AND TOXIC  
SUBSTANCES

SUBJECT: 625. Pentachloronitrobenzene (PCNB). Preliminary  
Notification of Adverse Effects in 90-Day Subchronic  
Oral Study 6(a)2

Tox. Chem. No. 640  
Project No. D180359

TO: Susan Cerrelli, PM Team # 73  
Special Review and  
Reregistration Division (H7508W)

FROM: Pamela M. Hurley, Toxicologist  
Section I, Toxicology Branch I  
Health Effects Division (H7509C)

*Pamela M. Hurley*  
7/16/92

THRU: Roger L. Gardner, Section Head  
Section I, Toxicology Branch I  
Health Effects Division (H7509C)

*Roger Gardner*  
7/16/92  
KB  
7/17/92

Submission: S421221

Background and Request:

Amvac Chemical Corporation has completed a 90-day subchronic oral study on PCNB in the rat. The study was conducted in order to assist in selecting the dose level for the chronic toxicity/oncogenicity study on PCNB. The dose levels selected for the 90-day oral study were 0, 5, 10, 100 and 1000 mg PCNB/kg/day (dosed 5 days per week) at a dose volume of 5 ml/kg. The histopathology evaluation has shown evidence of an increased incidence and severity of hyperplasia and hypertrophy of the follicular epithelium in the thyroid gland at the highest dose level tested (6/10 males and 5/10 females). Amvac has submitted to the Agency a preliminary 6(a)(2) notification letter summarizing these results. The Registrant expects to submit the final report to the Agency in July, 1992. The letter was sent to the Toxicology Branch (TB-I) as an FYI. TB-I was not asked to officially respond to the letter.

Toxicology Branch Response:

TB-I acknowledges the receipt of the preliminary notification of the possible 6(a)(2) data for the 90-day subchronic oral study on PCNB. Since the instructions state that

this letter was sent to TB-I as an FYI only, TB-I will wait for the final report before commenting on the results from the study.